Savant Capital LLC Invests $229,000 in Agios Pharmaceuticals, Inc. $AGIO

Savant Capital LLC acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,883 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

A number of other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. raised its position in Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 320 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 499 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Agios Pharmaceuticals by 0.3% in the 2nd quarter. Nordea Investment Management AB now owns 224,746 shares of the biopharmaceutical company’s stock worth $7,520,000 after purchasing an additional 573 shares in the last quarter. CWM LLC lifted its stake in Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 996 shares during the last quarter. Finally, Harbor Capital Advisors Inc. lifted its stake in Agios Pharmaceuticals by 3.6% during the second quarter. Harbor Capital Advisors Inc. now owns 37,024 shares of the biopharmaceutical company’s stock valued at $1,231,000 after purchasing an additional 1,295 shares during the last quarter.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Theodore James Jr. Washburn sold 8,546 shares of the stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the completion of the sale, the insider directly owned 868 shares of the company’s stock, valued at $32,003.16. This represents a 90.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Cecilia Jones sold 3,651 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the transaction, the chief financial officer directly owned 33,870 shares in the company, valued at $1,245,399.90. The trade was a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,099 shares of company stock valued at $620,092 over the last three months. 4.30% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Stock Down 50.9%

Shares of Agios Pharmaceuticals stock opened at $22.34 on Thursday. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $62.45. The stock has a market cap of $1.30 billion, a PE ratio of -3.19 and a beta of 0.89. The business has a fifty day simple moving average of $40.38 and a 200-day simple moving average of $36.91.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The firm had revenue of $12.90 million during the quarter, compared to the consensus estimate of $10.49 million. During the same period in the prior year, the business earned $16.22 EPS. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. Analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Ratings Changes

AGIO has been the topic of several research reports. Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $28.00 price target on the stock. in a report on Wednesday. Zacks Research raised Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. Scotiabank reduced their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. HC Wainwright reissued a “buy” rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $50.00.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.